A plasma telomeric cell-free DNA level in unaffected women with BRCA1 or/and BRCA2 mutations: a pilot study

被引:5
|
作者
Dey, Shatovisha [1 ]
Marino, Natascia [2 ,3 ]
Bishop, Kanokwan [1 ]
Dahlgren, Paige N. [1 ]
Shendre, Aditi [4 ]
Storniolo, Anna Maria [2 ,3 ]
He, Chunyan [5 ]
Tanaka, Hiromi [1 ]
机构
[1] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA
[2] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA
[3] IU Simon Canc Ctr, Susan G Komen Tissue Bank, Indianapolis, IN USA
[4] Indiana Univ, Dept Epidemiol, Richard M Fairbanks Sch Publ Hlth, Indianapolis, IN 46204 USA
[5] Univ Kentucky, Coll Med, Dept Internal Med, Markey Canc Ctr, Lexington, KY USA
基金
美国国家卫生研究院;
关键词
BRCA1; BRCA2; telomere; circulating cell-free DNA; qPCR; BREAST-CANCER; HIGH-RISK; LENGTH; HAPLOINSUFFICIENCY; METAANALYSIS; INSTABILITY; REPAIR;
D O I
10.18632/oncotarget.23767
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Plasma cell-free DNA (cfDNA) is a small DNA fragment circulating in the bloodstream originating from both non-tumor-and tumor-derived cells. A previous study showed that a plasma telomeric cfDNA level decreases in sporadic breast cancer patients compared to controls. Tumor suppressor gene products including BRCA1 and BRCA2 (BRCA1& 2) play an important role in telomere maintenance. In this study, we hypothesized that the plasma telomeric cfDNA level is associated with the mutation status of BRCA1&2 genes. To test this hypothesis, we performed plasma telomeric cfDNA quantitative PCR (qPCR)-based assays to compare 28 women carriers of the BRCA1& 2 mutation with age-matched controls of 28 healthy women. The results showed that the plasma telomeric cfDNA level was lower in unaffected BRCA1& 2 mutation carriers than in age-matched controls from non-obese women (BMI < 30), while there was no association between unaffected BRCA1& 2 mutation carriers and age-matched controls in obese women (BMI > 30). Moreover, the plasma telomeric cfDNA level applied aptly to the Tyrer-Cuzick model in non-obese women. These findings suggest that circulating cfDNA may detect dysfunctional telomeres derived from cells with BRCA1&2 mutations and, therefore, its level is associated with breast cancer susceptibility. This pilot study warrants further investigation to elucidate the implication of plasma telomeric cfDNA levels in relation to cancer and obesity.
引用
收藏
页码:4214 / 4222
页数:9
相关论文
共 50 条
  • [1] Oophorectomy in women with BRCA1 or BRCA2 mutations
    Burki, Talha Khan
    LANCET ONCOLOGY, 2014, 15 (04): : E156 - E156
  • [2] Circulating cell-free DNA (cfDNA) levels in BRCA1 and BRCA2 mutation carriers: A preliminary study
    Douvdevani, Amos
    Bernstein-Molho, Rinat
    Asraf, Keren
    Doolman, Ram
    Laitman, Yael
    Friedman, Eitan
    CANCER BIOMARKERS, 2020, 28 (03) : 269 - 273
  • [3] Bone Loss in Women with BRCA1 and BRCA2 Mutations
    Salyer, Chelsea
    Alabaster, Amy
    Hamilton, Isabella
    Stoller, Nicole
    Raine-Bennett, Tina
    Powell, C. Bethan
    GYNECOLOGIC ONCOLOGY, 2017, 147 (01) : 212 - 213
  • [4] Bone loss in women with BRCA1 and BRCA2 mutations
    Powell, C. Bethan
    Alabaster, Amy
    Stoller, Nicole
    Armstrong, Mary Anne
    Salyer, Chelsea
    Hamilton, Isabella
    Raine-Bennett, Tina
    GYNECOLOGIC ONCOLOGY, 2018, 148 (03) : 535 - 539
  • [5] Relevant risk for women with BRCA1 and BRCA2 mutations
    Furnival, Colin
    ANZ JOURNAL OF SURGERY, 2007, 77 (05) : 309 - 309
  • [6] Prevalence of founder mutations in the BRCA1 and BRCA2 genes among unaffected women from the Bahamas
    Trottier, M.
    Lunn, J.
    Butler, R.
    Curling, D.
    Turnquest, T.
    Francis, W.
    Halliday, D.
    Royer, R.
    Zhang, S.
    Li, S.
    Thompson, I.
    Donenberg, T.
    Hurley, J.
    Akbari, M. R.
    Narod, S. A.
    CLINICAL GENETICS, 2016, 89 (03) : 328 - 331
  • [7] Risk of cardiovascular disease in women with BRCA1 and BRCA2 mutations
    Powell, C. Bethan
    Alabaster, Amy
    Armstrong, Mary Anne
    Stoller, Nicole
    Raine-Bennett, Tina
    GYNECOLOGIC ONCOLOGY, 2018, 151 (03) : 489 - 493
  • [8] BRCA1 and BRCA2 mutations in women from Shanghai China
    Suter, NM
    Ray, RM
    Hu, YW
    Lin, MG
    Porter, P
    Gao, DL
    Zaucha, RE
    Iwasaki, LM
    Sabacan, LP
    Langlois, MC
    Thomas, DB
    Ostrander, EA
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2004, 13 (02) : 181 - 189
  • [9] Clinical management of women with genomic BRCA1 and BRCA2 mutations
    Chang, J
    Elledge, RM
    BREAST CANCER RESEARCH AND TREATMENT, 2001, 69 (02) : 101 - 113
  • [10] Benefit of prophylactic mastectomy for women with BRCA1 or BRCA2 mutations
    Miller, LA
    Singer, ME
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2000, 283 (23): : 3070 - 3070